Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. (CYTO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cyto · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Altamira Therapeutics Ltd. (CYTO) measures how much investors pay for each dollar of the company's trailing earnings. CYTO's current PE ratio of N/A is calculated by dividing its stock price of $0.30 by its TTM earnings per share of -$14.81.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2011 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Altamira Therapeutics Ltd.You CYTO | $1M | N/A | — | -$14.81 |
 Bellicum Pharmaceuticals, Inc. BLCM | $1M | N/A | — | -$0.81 |
 CohBar, Inc. CWBR | $1M | N/A | — | -$4.13 |
 HTG Molecular Diagnostics, Inc. HTGMQ | $0M | N/A | — | -$24.28 |
 Impel Pharmaceuticals Inc. IMPL | $1M | N/A | — | -$5.52 |
 Infinity Pharmaceuticals, Inc. INFIQ | $0M | N/A | — | -$0.50 |
 NeuBase Therapeutics, Inc. NBSE | $1M | N/A | — | -$21.08 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $0.00 | — | |
2023-12-31 FY2023 | — | $-14.81 | — | |
2022-12-31 FY2022 | — | $-582.57 | — | |
2021-12-31 FY2021 | — | $-515.11 | — | |
2020-12-31 FY2020 | — | $-545.39 | — | |
2019-12-31 FY2019 | — | $-455.96 | — | |
2018-12-31 FY2018 | — | $-2892.08 | — | |
2017-12-31 FY2017 | — | $-22321.90 | — | |
2016-12-31 FY2016 | — | $-35728.27 | — | |
2015-12-31 FY2015 | — | $-36790.93 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Altamira Therapeutics Ltd. (CYTO) measures how much investors pay for each dollar of the company's trailing earnings. CYTO's current PE ratio of N/A is calculated by dividing its stock price of $0.30 by its TTM earnings per share of -$14.81.
Frequently asked questions
CYTO pe ratio · 6 questionsCYTO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.30 and TTM EPS of -$14.81. Data sourced from Financial Modeling Prep via CYTO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Altamira Therapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09